tetano
Editor, Senior Moderator
Sci Rep. 2018 Mar 15;8(1):4653. doi: 10.1038/s41598-018-22875-9.
[h=1]Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance.[/h] Zhang J[SUP]1[/SUP], Hu Y[SUP]1[/SUP], Foley C[SUP]2[/SUP], Wang Y[SUP]1[/SUP], Musharrafieh R[SUP]2[/SUP], Xu S[SUP]2[/SUP], Zhang Y[SUP]2[/SUP], Ma C[SUP]3[/SUP], Hulme C[SUP]2[/SUP], Wang J[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses are respiratory pathogens that are responsible for seasonal influenza and sporadic influenza pandemic. The therapeutic efficacy of current influenza vaccines and small molecule antiviral drugs is limited due to the emergence of multidrug-resistant influenza viruses. In response to the urgent need for the next generation of influenza antivirals, we utilized a fast-track drug discovery platform by exploring multi-component reaction products for antiviral drug candidates. Specifically, molecular docking was applied to screen a small molecule library derived from the Ugi-azide four-component reaction methodology for inhibitors that target the influenza polymerase PA[SUB]C[/SUB]-PB1[SUB]N[/SUB] interactions. One hit compound 5 was confirmed to inhibit PA[SUB]C[/SUB]-PB1[SUB]N[/SUB] interactions in an ELISA assay and had potent antiviral activity in an antiviral plaque assay. Subsequent structure-activity relationship studies led to the discovery of compound 12a, which had broad-spectrum antiviral activity and a higher in vitro genetic barrier to drug resistance than oseltamivir. Overall, the discovery of compound 12a as a broad-spectrum influenza antiviral with a high in vitro genetic barrier to drug resistance is significant, as it offers a second line of defense to combat the next influenza epidemics and pandemics if vaccines and oseltamivir fail to confine the disease outbreak.
PMID: 29545578 DOI: 10.1038/s41598-018-22875-9
Free full text
[h=1]Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance.[/h] Zhang J[SUP]1[/SUP], Hu Y[SUP]1[/SUP], Foley C[SUP]2[/SUP], Wang Y[SUP]1[/SUP], Musharrafieh R[SUP]2[/SUP], Xu S[SUP]2[/SUP], Zhang Y[SUP]2[/SUP], Ma C[SUP]3[/SUP], Hulme C[SUP]2[/SUP], Wang J[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses are respiratory pathogens that are responsible for seasonal influenza and sporadic influenza pandemic. The therapeutic efficacy of current influenza vaccines and small molecule antiviral drugs is limited due to the emergence of multidrug-resistant influenza viruses. In response to the urgent need for the next generation of influenza antivirals, we utilized a fast-track drug discovery platform by exploring multi-component reaction products for antiviral drug candidates. Specifically, molecular docking was applied to screen a small molecule library derived from the Ugi-azide four-component reaction methodology for inhibitors that target the influenza polymerase PA[SUB]C[/SUB]-PB1[SUB]N[/SUB] interactions. One hit compound 5 was confirmed to inhibit PA[SUB]C[/SUB]-PB1[SUB]N[/SUB] interactions in an ELISA assay and had potent antiviral activity in an antiviral plaque assay. Subsequent structure-activity relationship studies led to the discovery of compound 12a, which had broad-spectrum antiviral activity and a higher in vitro genetic barrier to drug resistance than oseltamivir. Overall, the discovery of compound 12a as a broad-spectrum influenza antiviral with a high in vitro genetic barrier to drug resistance is significant, as it offers a second line of defense to combat the next influenza epidemics and pandemics if vaccines and oseltamivir fail to confine the disease outbreak.
PMID: 29545578 DOI: 10.1038/s41598-018-22875-9
Free full text